Day: April 18, 2025

            Vallourec: Availability of information relating to the Combined (Ordinary and Extraordinary) Shareholders’ Meeting of 22 May 2025 Meudon (France), April 18, 2025 Vallourec’s Ordinary and Extraordinary Shareholders’ Meeting will be held on 22 May 2025 at 2:00 p.m. at Espace Verso, 52 rue de la Victoire 75009 Paris. The prior notice of meeting published in the Bulletin des Annonces Légales Obligatoires of April 7, 2025, the notice of meeting including the agenda, draft resolutions and reports thereon, as well as the procedures for participating in the Meeting and voting are available on Vallourec’s website (www.vallourec.com). All useful information relating to this Meeting is regularly updated on this page of the website. The documents referred to in Article R. 225-83 of the French...

Amsterdam, 18 April 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) announces that AMG Lithium BV has signed an exclusive agreement with Grupo Lagoa to become the first producer of spodumene concentrate in Portugal with an initial capacity of 8,000–9,000 tons per annum by the first half of 2027, pending government approvals. This exclusive agreement builds upon the positive results from our joint pre-engineering efforts since the first announcement of our partnership on August 17, 2023. The capital expenditures of approximately 10 million Euros for this commercially sized pilot plant will be provided by AMG in the form of a loan to Grupo Lagoa. In exchange, AMG secures accelerated access to local production of spodumene in Europe to supply its lithium refinery in Germany. The supply from...

FORT WAYNE, Ind., April 18, 2025 (GLOBE NEWSWIRE) — Vera Bradley (NASDAQ: VRA) (the “Company”) today announced that long-time board member Frances P. Philip will not stand for re-election at the upcoming 2025 Shareholder Meeting. Ms. Philip joined the Company’s Board in 2011 and has served as a member on both the Talent and Compensation Committee, as well as the Nominating, Governance and Sustainability Committee during her tenure. Ms. Philip has served as the Lead Independent Director since 2022, overseeing the Company’s business with insights stemming from the extensive product development, branding, marketing, and retail experience she possesses. Robert Hall, Chairman of the Vera Bradley board of Directors, commented, “Frances has been a highly respected and influential member of the Company’s Board of Directors over the past...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) will report first-quarter 2025 earnings on Tuesday, April 22. The company will present results on a webcast beginning at 8:30 a.m. Eastern Time. First-quarter 2025 materials will be available at 7:00 a.m. ET on Verizon’s Investor Relations website, https://www.verizon.com/about/investors. These materials will include:Detailed information on Verizon’s first quarter results, including a recording and transcript of management’s commentary; Verizon’s earnings news release; and Financial tables.Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment. “People with chronic spontaneous urticaria experience sudden, unpredictable...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment. Kenneth MendezPresident and Chief Executive Officer at the Asthma and...

Paris, Friday, April 18th, 2025 At the Annual Shareholders’ Meeting of LVMH Moët Hennessy Louis Vuitton held on Thursday, April 17th, 2025, approval was given for the payment of a dividend for financial year 2024 of 13.00 Euros per share.Taking into account the 5.50 Euros paid on Wednesday, December 4th, 2024, the balance of 7.50 Euros will be paid on Monday, April 28th, 2025. The last trading day with dividend rights is Wednesday, April 23rd, 2025. LVMHLVMH Moët Hennessy Louis Vuitton is represented in Wines and Spirits by a portfolio of brands that includes Moët & Chandon, Dom Pérignon, Veuve Clicquot, Krug, Ruinart, Mercier, Château d’Yquem, Domaine du Clos des Lambrays, Château Cheval Blanc, Colgin Cellars, Hennessy, Glenmorangie, Ardbeg, Belvedere, Woodinville, Volcán de mi Tierra, Chandon, Cloudy Bay, Terrazas de los Andes,...

Boulogne-Billancourt, April 18, 2025 Disclosure of Share Capital and Voting Rights(Pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the general Regulations of the Autorités des Marchés Financiers) Registered name of the issuer: CEGEDIM SADate Shares outstanding Total potential voting rights Exercisable voting rights*March 31, 2025 14,097,155 22,031,685 21,700,558* excluding rights attached to share held in treasuryAttachmentDisclosure-share-VR-31march2025

Mr. Davies was Previously the Company’s Chief Commercial Officer Knoxville, TN, April 18, 2025 (GLOBE NEWSWIRE) — Healthcare Integrated Technologies Inc. (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the appointment of Theo Davies from Chief Commercial Officer to Chief Revenue Officer (“CRO”), effective immediately. Prior to Mr. Davies being the Company’s Chief Commercial Officer, Mr. Davies was a former Google executive, who was the Head of Sales Enablement for Asia-Pacific. Mr. Davies continues to bring a wealth of global expertise and leadership to HITC. His exceptional background, including a master’s in mathematics, from the University of Edinburgh and an MBA from India’s top business school, SP Jain, Mr. Davies has consistently demonstrated his ability to develop world-class...